Sector Expert: Hugh Cleland

Roadmap Capital Inc.

Image: Hugh Cleland

Hugh Cleland, BA, CFA, is cofounder, CEO, president, CIO and principal portfolio manager of the Roadmap Innovation Fund I and the Roadmap Trust. He is also portfolio manager, through a subadvisory contract between Roadmap Capital and BluMont Capital, of the BluMont Innovation PE Strategy Fund. Cleland earned a bachelor's degree with honors from Harvard University, and his CFA designation in 2001. After graduating from Harvard, Cleland worked in the research department at Midland Walwyn Capital (subsequently Merrill Lynch Canada) as research associate to the senior telecommunications services analyst. From March 1998 to March 2001, Cleland worked at Interward Capital Corp., first as an analyst, and later as associate portfolio manager, specializing in technology equities. He was founding portfolio manager at Northern Rivers Capital Management, where he worked from May 2001 until Northern Rivers was acquired by BluMont Capital in February 2010. Together with Riadh Zine, he cofounded Roadmap Capital Inc. in August 2013.



Recent Quotes

"If the biotech space gets as heated as we think it will, BLU could very well trade above $10/share."

The Life Sciences Report Interview with Hugh Cleland (9/17/14)
more >

"BLU presented to our advisory board and came out as one of the favorites."

The Life Sciences Report Interview with Hugh Cleland (3/19/14)
more >

"CTH has made huge strides, including closing a financing of $7.3M getting funding from the Michael J. Fox Foundation."

The Life Sciences Report Interview with Hugh Cleland (6/27/13)
more >

"I am revisiting VRS after having made money on it in the past."

The Life Sciences Report Interview with Hugh Cleland (6/27/13)
more >

"The Angelo VMS preliminary data has been excellent, and that suggests FDA approval is likely for VPT."

The Life Sciences Report Interview with Hugh Cleland (11/15/12)
more >

"Financing will give investors even more confidence that LPTN will have the capital it needs."

The Life Sciences Report Interview with Hugh Cleland (11/15/12)
more >

"CTH could very well be worth more than CA$200M in three to five years."

The Life Sciences Report Interview with Hugh Cleland (11/15/12)
more >

"I consider VPT to be a low-risk/high-reward opportunity."

The Life Sciences Report Interview with Hugh Cleland (8/9/12)
more >



Due to permission requirements, not all quotes are shown.